Company news
Nervgen Pharma Corp. (NASDAQ:NGEN) news
Nervgen Pharma Corp. news releases on 6ix. Latest, Sep 25, 2026: NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting…
Press releases & updates
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
September 25, 2026
NervGen to Host Inaugural R&D Day on September 30, 2026
September 9, 2026
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 13, 2026
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
May 26, 2026
NervGen Announces Proposed Public Offering of Securities
May 21, 2026
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
May 20, 2026
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
May 18, 2026
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
April 27, 2026
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
April 6, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 30, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
March 11, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
March 3, 2026
NervGen Pharma to Participate at Upcoming Investor Conferences
February 18, 2026
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
February 11, 2026
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
February 11, 2026
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
February 8, 2026
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
January 20, 2026